| Abstrakt: |
A recent study from the University of Calgary explores the current perspectives and future possibilities for the treatment of cirrhotic cardiomyopathy (CCM). CCM is a condition characterized by cardiac dysfunction in individuals with cirrhosis, and it significantly contributes to mortality and morbidity in liver transplant patients. The traditional management for non-cirrhotic cardiomyopathies is not applicable to CCM, so alternative therapeutic strategies are needed. The study discusses the potential use of non-selective beta-blockers (NSBBs) and other drugs with antioxidant, anti-inflammatory, and anti-apoptotic functions. However, further research is needed to determine the efficacy of these treatments. [Extracted from the article] |
